For the year ending 2025-12-31, SLXNW has $7,215K in assets. $4,612K in debts. $5,991K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents, at carrying value | 5,991 | |||
| Restricted cash and cash equivalents, current | 27 | |||
| Prepaid expense, current | 570 | |||
| Other assets, current | 49 | |||
| Assets, current | 6,637 | |||
| Restricted cash, noncurrent | 57 | |||
| Deposits assets, noncurrent | 84 | |||
| Property, plant and equipment, net | 25 | |||
| Operating lease, right-of-use asset | 412 | |||
| Assets, noncurrent | 578 | |||
| Assets | 7,215 | |||
| Accounts payable, current | 787 | |||
| Operating lease, liability, current | 182 | |||
| Employee-related liabilities, current | 879 | |||
| Other accounts payable and accrued liabilities | 910 | |||
| Represent the amount of underwriting promissory notes in current liabilities | 0 | |||
| Liabilities, current | 2,758 | |||
| Operating lease, liability, noncurrent | 286 | |||
| Represent the amount of promissory notes to related parties | 1,568 | |||
| Liabilities, noncurrent | 1,854 | |||
| Liabilities | 4,612 | |||
| Common stock, value, issued | 42 | |||
| Additional paid in capital | 57,727 | |||
| Retained earnings (accumulated deficit) | -55,166 | |||
| Equity, attributable to parent | 2,603 | |||
| Liabilities and equity | 7,215 | |||
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)